Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?

Table 1 Studies reporting the effect and safety of first-line therapies in advanced hepatocellular carcinoma

	IMbrave: Phase III, open-label		REFLECT: Phase III, open-label		CheckMate-459: Phase III, open-label
	Atezo + Bev	Sorafenib	Lenvatinib	Sorafenib	Nivolumab	Sorafenib
n	336	165	478	476	371	372
Age, median	64	66	63	62	65	65
≥ 65 yr, %	48	55	44	41	NR	NR
Male, %	82	83	85	84	85	85
Asia, %	56	58	70	68	NR	NR
ECOG 1, %	38	38	36	37	27	30
AFP ≥ 200 ng/mL, %	43	45	46	39	39	43
HBV, %	49	46	53	48	31	31
HCV, %	21	22	19	26	23	23
Nonviral, %	30	32	28	26	45	45
MVI trunk			Excluded		Excluded
MVI, %	38	43	23	19	NR	NR
EH, %	63	56	61	62	NR	NR

AFP: Alpha-fetoprotein; Atezo + Bev: Atezolizumab + bevacizumab; ECOG: Eastern Cooperative Oncology Group; EH: Extrahepatic tumor disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus; MVI: Macrovascular invasion or neoplastic thrombosis of the main portal trunk; NR: Not reported.